Home > Boards > US Listed > Medical - Equipment >

CHF Solutions, Inc (CHFS)

Add CHFS Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/16/2018 2:14:52 PM - Followers: 62 - Board type: Free - Posts Today: 0

Sunshine Heart
Corporate Office
United States of America
Sunshine Heart, Inc.
12988 Valley View Road
Eden Prairie, MN 55344
Phone +1 952 345 4200
Dr Elaine Stead
Vice President, Corporate Development
+61 (0) 412 637 023

Sunshine Heart focuses on an innovative cardiac assist therapy to treat heart patients who represent a large and under-served market segment and provide a significant opportunity for the company. Unfortunately, these Class IV patients, despite optimal drug therapy, have persistent symptoms and their options are very limited. Surgical approaches usually involve complex open-heart surgery or heart transplantation.
C-Pulse systemSunshine Heart's C-Pulse® Heart Assist System is an innovative approach to assist the heart's function, not replace it and may be implanted using a minimally invasive approach. The C-Pulse Heart Assist System is designed to treat clinical symptoms associated with Class III and ambulatory Class IV heart failure, sometimes also referred to as moderate and severe failure. Patients associated with Class III and ambulatory Class IV heart failure are typically unable to engage in normal activities, compromising their quality of life.


The C-Pulse Heart assist system is designed to treat clinical symptoms associated with Class III and ambulatory Class IV heart failure. These symptoms normally include shortness of breath, dizziness, low blood pressure and fluid retention. Patients associated with Class III and ambulatory Class IV heart failure are typically unable to engage in normal activities, compromising their quality of life. The C-Pulse Heart Assist System may be implanted through a minimally invasive or full sternotomy technique. 

The C-Pulse System's design is based on proven balloon counter-pulsation technology to assist the heart by reducing the workload of the left ventricle. During inflation of the balloon, blood flow is increased to the coronary arteries, thereby providing additional oxygen which is vital to a failing heart. During deflation, theworkload or pumping required by the left heart is reduced. The balloon inflation and deflation is synchronized to the patient's ECG, similar to a pacemaker. Potential benefits of the technology, which are currently being analyzed in clinical trials, are relief of shortness of breath, increased physical activity, and improved cardiac function.

The C-Pulse is designed to improve heart function in three ways:


More blood flow from the heart called increased cardiac output


More oxygen to the heart muscle, called increased coronary blood flow


Less work for the heart, called decreased afterload

Shares Outstanding:6.28M
Free trading shares: 2.62M

Latest news:
SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire -06/07/12)- Sunshine Heart, Inc. (SSH) (SHC.AX), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced that the company has been granted approval by Health Canada to use its next generation C-Pulse® Heart Assist System driver in ongoing clinical studies at Royal Victoria Hospital. The new C-Pulse driver is designed to provide heart failure patients with enhanced patient comfort and performance. The C-Pulse System is a new investigational therapeutic approach based on proven balloon counter-pulsation technology for the treatment of patients with Class III and ambulatory Class IV heart failure.
The C-Pulse driver now comes as a single unit that is half the size, lighter and quieter than the first generation technology. The driver also features a number of software enhancements. The C-Pulse System is currently in an investigational study at Royal Victoria Hospital. The prospective study is designed to evaluate the safety and performance of the C-Pulse System as a treatment for patients with moderate to severe heart failure. To date, four patients have been implanted with the initial C-Pulse System. The company has received Health Canada approval to expand the number of participants in the trial to 20 patients. All trial participants will receive the new C-Pulse driver, which will be used in ongoing and future clinical studies.
"We are pleased to have received Health Canada approval of our next generation C-Pulse driver technology for clinical use," said Dave Rosa, CEO of Sunshine Heart. "We enhanced the driver based on results from our feasibility trial and feedback from physicians and patients. With the reduced size, weight and noise reduction, we expect improvements in patient quality of life due to enhanced comfort and performance. We look forward to making this new technology available to patients enrolled in our clinical studies in Canada in the coming weeks, as well the United States and Europe thereafter."
The external C-Pulse driver inflates and deflates the balloon which is secured by a cuff around the outside of the ascending aorta, the main blood vessel of the heart. The cuff and heart signal sensing wires are attached to the external C-Pulse driver, which inflates and deflates the balloon in sequence with the electrocardiogram (ECG) signal to assist heart function and the pumping capacity of the heart. The balloon deflects the aorta in a "thumb-printing" manner, which is intended to minimize aortic wall strain and maximize blood volume displacement per beat.
About Class III Heart Failure
Heart failure is a common condition in which the heart becomes unable to pump sufficient blood to meet the body's needs. More than five million people in the United States have heart failure, resulting in more than 300,000 deaths each year(1). Heart failure is a progressive condition and typically results from damage to the heart muscle arising from a heart attack or virus.
Cardiologists use the New York Heart Association (NYHA) classification system to define the four classes of heart failure; each class is determined by rating a patient's symptoms to everyday activities and quality of life. More than 1.5 million U.S. heart failure patients are in the Class III or moderate heart failure category which is defined by the limitation of physical activity(2). These patients are comfortable at rest, but levels of activity regarded as less than ordinary cause fatigue, palpitation and/or shortness of breath. The most common treatments for Class III heart failure are drugs, lifestyle adjustments, family education, device therapy (i.e. heart failure pacemaker with or without a defibrillator) or surgery. These standard treatments often do not resolve the progression of heart failure leaving patients without any additional options, hence the need for new treatments for patients living with the disease.
Caution - Investigational device. Limited by Federal (or United States) law to investigational use.
SSH chart

Preliminary Data from european trial, delivered at the 34th Annual International Society for Heart and Lung Transplant April 10th, 2014
Surgical implantation was successful in all patients and does not require cardiopulmonary bypass. Follow-up ranges from 5 days - 6 months with a cumulative follow-up of 493 days. No stroke, myocardial infarction, major bleeding or major infection has occurred due to the device. One patient developed tachycardia with worsening heart failure 12 hours after surgery without stabilization under medication and underwent left ventricular assist device implantation after 5 days.
4 patients improved clinically under the C-Pulse system with three patients improving their functional status by one NYHA class. So far LVEF has increased by an average of 10-15% in the 3 patients with the longest follow-up. One patient is post-op day 7 and has not yet been assessed for efficacy. Conclusion: The C-Pulse system seems to be a promising therapeutic option and may improve cardiac function over time.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SSH News: Statement of Changes in Beneficial Ownership (4) 09/20/2017 04:25:27 PM
SSH News: Amended Statement of Beneficial Ownership (sc 13d/a) 09/20/2017 04:23:20 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1059   That price is split adjusted Lion33 03/16/18 02:14:52 PM
#1057   It was never at those prices. They Vector93 03/16/18 12:13:53 PM
#1056   What are you talking about? Go to myjo 03/16/18 11:59:30 AM
#1055   Because of reverse splits, the share price was Vector93 03/16/18 11:49:13 AM
#1054   Company’s financial fundamentals are totally irrelevant at this myjo 03/16/18 11:25:28 AM
#1053   possibly bear trap here always the case with John/bal 03/16/18 11:03:56 AM
#1052   very risky to short on so well positioned ash111 03/16/18 10:23:24 AM
#1051   Low-float no-debt new marketing chief with solid resume. myjo 03/16/18 10:00:01 AM
#1050   A/o today company is almost debt-free. Cash on ash111 03/16/18 08:52:11 AM
#1049   In 2012 CHFS was trading at 13000$. In myjo 03/15/18 09:39:20 PM
#1048   * * $CHFS Video Chart 03-15-18 * * ClayTrader 03/15/18 04:58:34 PM
#1047   Excellent due diligence Ash! Thank you for 2day2morrow 03/15/18 04:11:16 PM
#1046   buy pressure continues since yesterday. accelerating now. company ash111 03/15/18 03:38:51 PM
#1045   Nice price move today, just the start - imo. 2day2morrow 03/15/18 10:30:55 AM
#1044   volume say another big run is expected. John/bal 03/15/18 09:47:14 AM
#1043   CHFS delivered again. Thanks Ash ANIA77 03/15/18 09:25:51 AM
#1042   3.81s peterus 03/15/18 08:58:17 AM
#1041   nice buy what pps did you get? [SMART MONEY] 03/15/18 08:27:50 AM
#1040   Nice AH action jonnyvs 03/14/18 05:12:24 PM
#1039   Agreed. CHFS about to have leggs. 2day2morrow 03/14/18 01:25:54 PM
#1038   CHFS waking for solid reasons.Market potential is HUGE ash111 03/14/18 11:47:39 AM
#1037   Just bought 5k shares peterus 03/14/18 11:45:25 AM
#1036   Did you try contacting company? Are they responding? myjo 02/28/18 03:55:26 PM
#1035   Yes, I can't find a press release for Knicc 02/28/18 03:24:52 PM
#1034   Quarterly earnings announcement as per TDA before market myjo 02/28/18 03:13:08 PM
#1033   TDA says before market open tomorrow. Knicc 02/28/18 01:13:57 PM
#1032   Does anyone know when’s their quarterly earning’s announcement? myjo 02/28/18 10:53:04 AM
#1031   Nice to the breakout. Hopefully this will continue. mlebo 02/27/18 11:10:51 AM
#1030   Having an awesome resume; how will that so-called myjo 02/15/18 04:48:34 PM
#1029   Awesome Resume.looking strong Towards Monday's Presentation. ash111 01/26/18 04:59:03 PM
#1028   News. mlebo 01/24/18 08:55:52 AM
#1027   CHFS waking towards Catalysts,1. "In the third quarter, ash111 01/19/18 10:17:41 AM
#1026   I rebought today at 3.58 or so for reb329 01/08/18 03:30:45 PM
#1025   Up now about $17 grand. I will wait keekee 01/08/18 03:27:14 PM
#1024 just have to ask whether the group keekee 01/08/18 03:05:30 PM
#1023   Almost 400000 shares exercised at $3.50 keekee 01/08/18 12:04:17 PM
#1022   LOl. insiders loading at the $3.50 level like keekee 01/08/18 12:02:24 PM
#1021   Not sure of any other stock in this keekee 01/03/18 11:05:18 AM
#1020   Bidding to re-enter now with a couple of keekee 01/03/18 11:03:36 AM
#1019   Got 3k at $3.57 as it ran up. keekee 12/27/17 03:42:02 PM
#1018   Seems like all the tax loss sellers are keekee 12/27/17 12:49:17 PM
#1017   80% gain this week for CHFS. watch nokomis 12/11/17 01:50:53 PM
#1016   Don't post any more on message boards! Waste makingbiigdough 12/11/17 11:56:55 AM
#1015   Seems to be holding, needs more volume to reb329 12/11/17 11:24:12 AM
#1014   CHFS how high will it go is the nokomis 12/11/17 11:14:45 AM
#1013   CHFS macd crossover is very bullish. Due for nokomis 12/11/17 10:40:22 AM
#1012   Looking forward to Monday, I have about 1500 reb329 12/10/17 02:44:08 PM
#1011   He took a 13.1% Stake in the company. Dlicious1 12/09/17 03:49:39 PM
#1010   Appreciate the response. What exactly is a 13.1 Ducatijc80 12/09/17 03:02:35 PM
#1009   Li Chiang just took a 13.1 stake in Dlicious1 12/09/17 12:39:55 PM